Jazz Pharmaceuticals' 2025 Vision Seems Optimistic

Feb. 09, 2022 10:31 AM ETJazz Pharmaceuticals plc (JAZZ)5 Comments

Summary

  • Jazz Pharmaceuticals laid out its 2025 vision at the J.P. Morgan Healthcare Conference last month.
  • The company expects to generate $5 billion in revenues in 2025 and a five percentage points operating margin improvement.
  • The margin goal seems achievable but there are risks on the revenue side given the uncertainty around the company's oxybate franchise.
  • $5 billion in 2025 would be the very high end of my estimate range, but I can see the company creating shareholder value even if it falls short of its goal.
  • Looking for more investing ideas like this one? Get them exclusively at Growth Stock Forum. Learn More »

Man"s hand drawing growth chart for the year 2025.

Erik_V/iStock via Getty Images

Jazz Pharmaceuticals (NASDAQ:JAZZ) laid out its 2025 vision at the J.P. Morgan Healthcare Conference in early January. The company expects to generate $5 billion in annual revenues and it also expects a five percentage point improvement

JAZZ performance versus IBB and XBI

JAZZ performance versus IBB and XBI (Ycharts)

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

This article was written by

ONeil Trader profile picture
7.23K Followers
Discovering growth and biotech stocks with significant upside potential
Former stockbroker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on growth and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection.

My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

Exclusive research: http://seekingalpha.com/author/oneil-trader/research

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Recommended For You

Comments (5)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.